Sodium–glucose co-transporter-2 inhibitors are becoming a cornerstone of therapy for type 2 diabetes, kidney disease and heart failure.

Managing cardiovascular risk factors is crucial for improving the overall survival of patients and the outcomes of future abdominal aortic aneurysm repair.

Medicare Benefits Schedule rules regarding sleep study eligibility have recently changed and incorporate validated questionnaires of obstructive sleep apnoea risk and subjective sleepiness.

Diagnosis of PCOS in an Aboriginal primary care setting is being performed correctly and at a young age; however, subsequent screening of cardiometabolic risk and emotional wellbeing needs more work.

This article explores the impact of genetics on cardiovascular diseases and its implications for GPs.

In this issue of AJGP, we cover a wide range of cardiovascular conditions that GPs encounter in everyday practice, providing up-to-date information and management guidelines based on current evidence.

More than 360 cardiovascular disease risk equations have been developed, many incorporating risk factors not included in the Framingham Risk Equation.

An update on the genetic basis of sudden cardiac death (SCD) in the young and the clinical aspects of caring for families affected by SCD.

Scabies, an under-appreciated global health concern, needs to be considered in the differential of any pruritic cutaneous dermatoses.

Retina-predicted cardiovascular disease scores offer an accurate and convenient way to measure atherosclerotic cardiovascular disease risk.

Ambulatory blood pressure monitoring is the reference standard for diagnosing blood pressure abnormalities and should be used when possible.

Physical inactivity is a major modifiable contributor to the global burden of cardiovascular disease morbidity and mortality.

An absolute risk–based approach is superior to the traditional individual risk factor approach when calculating cardiovascular disease risk.

The study confirms under-treatment of Australian adults at high cardiovascular disease risk and indicates potential for health gains with increased implementation of evidence-based guidelines.

The usefulness of modern point-of-care tests for group A streptococci (GAS) is determined by the presence of carriers of GAS.